May 2019CIOAPPLICATIONS.COM9researchers at Children's Mercy have used this resource to explore questions related to opioid utilization, outcomes research, drug safety and other important topics. Also, I am interested in advanced visualization of biological and clinicalstructures. My enthusiasmfor that led me to work with the Microsoft HoloLens tovisualize biological structures including proteins andpatient generated anatomical structures. Integrating mixed reality with a wide variety of data sources is another exciting emerging opportunity.What are the strategic points that you go by to steer the company forward? As a community, scientists have strong individual preferences for niche applications, "best of breed" capabilities and or even custom-developed applications. As a growing organization, we recognize the need to standardize research processes while providing agility where needed. A key part of our strategy has been to embrace proven platforms, cloud-based whenever possible, for standardized research processes while working with our researchers to ensure that their unique needs are met. Toward this goal, we are in the middle of a large migration to a Software as a Service (SaaS) implementation of a suite of research applications. This helps my team focus our creative energies on the needs of specific research projects.Mentoring is also a strategic priority. I have been mentoring clinical researchers at Children's Mercy Hospital as they use this data and informatics to support their projects. In the process of mentoring, I find it exciting to help clinical researchers cultivate a "data science" mindset. How do you build transformative systems? Could you provide some examples that you have undertakenin the recent past?When designing and building transformative systems, it is critical to always focus on the beneficiaries of the system. For us, that is ultimately the children who receive care at Children's Mercy. When a system is designed to deliver tangible benefits and solve practical problems, it will be accepted and embraced. For projects that I lead, I encourage my team to begin by talking with stakeholders, shadowing them as they do their work and visiting them in their labs to see the instruments and workflows that are involved in the science. This helps improve communication between the developers and the stakeholders and the end result is always better when we have this level of engagement.What would be a piece of advice that you could impart to your colleagues who look to embark on a similar venture along the lines of your expertise?I think it is important to approach a relationship with vendors as a partnership rather than a zero-sum game with a winner and a loser.When possible, seek win-win solutions, these are much more sustainable. Based on my 16 years of professional experience working ata large vendor, I understand what they need to accomplish, but I also need to be a good steward of ourorganizational resources. With a true partnership everybody wins.How would you see the evolution a few years from now with regard to disruptions and transformations within the arena? The use of AI and machine learning in the life sciences have proven to be vital in drug discovery, genomic analysis and image analysis. I think the volume and complexity of data that is being generated both in diagnostic and research labscontinues to increase and there is undoubtedly a need to apply the data science tool kit to augment analysis. At the same time, we have to continue to focus on safety and appropriate use of those technologies. Finding the balance between the rapid growth of the complexity and ensuring that the appropriate logic is used to interpret the data is also equally essential. We need to approach the relationship with vendors as a partnership rather than a zero-sum gameMark Hoffman
< Page 8 | Page 10 >